Clinical Trials Logo

Colorectal Cancer clinical trials

View clinical trials related to Colorectal Cancer.

Filter by:

NCT ID: NCT03794128 Recruiting - Colorectal Cancer Clinical Trials

A Study for the Production of a Personalized Neoantigen Cancer Vaccine

Start date: July 25, 2018
Study type: Observational

The purpose of this study is to evaluate the feasibility of manufacturing a personalized neoantigen cancer vaccine, which involves predicting if the patient's neoantigens and generating a vaccine that encodes the predicted neoantigens.

NCT ID: NCT03793335 Not yet recruiting - Colorectal Cancer Clinical Trials

Individually Tailored Strategies for the Precision Prevention of Gastric Cancer and Colorectal Cancer in the Community

Start date: April 1, 2019
Study type: Observational

Gastric cancer is a global health threat. Helicobacter pylori is now recognized as the main risk factor that initiates this process; hence, H. pylori eradication has been considered the most effective method to ameliorate the burden of gastric cancer. Serum pepsinogen levels reveal the current atrophy of the stomach and predict gastric cancer risk. A risk prediction model with the combination of H. pylori infection and serum pepsinogen level could identify the highest-risk gastric cancer patients. Colorectal cancers (CRC) rank second and third as the leading causes of cancer-related death in men and women, respectively. For CRC prevention, a two-stage approach using the fecal immunochemical test (FIT) is popular; besides, the FIT levels may serve as a guide for priority setting in prompting residents to undergo colonoscopy. Therefore, the effectiveness and utility of aggressive referral confirmatory diagnosis protocol in a colorectal cancer screening program for those with high FIT levels urgently need to evaluate.

NCT ID: NCT03792568 Recruiting - Colorectal Cancer Clinical Trials

ALK Inhibitor in Metastatic Colorectal Cancer With ALK Mutation.

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

This clinical trial aims to evaluate the efficacy, safety of ALK inhibitor in Metastatic Colorectal Cancer Patients with ALK mutation.

NCT ID: NCT03790475 Recruiting - Colorectal Cancer Clinical Trials

Participation in Competing Strategies for Colorectal Cancer Screening - a Randomized Health Services Study Within the National Screening Program in Poland

Start date: August 25, 2018
Phase: N/A
Study type: Interventional

The PICCOLINO is a randomized health services study performed within the framework of the Polish Colonoscopy Screening Program (PCSP) in Poland. Within the study 12,298 eligible persons between 55 and 64 years of age will be drawn from the Population Registry and randomly assigned in a 1:1:1 ratio to receive an invitation to participate in one of the three screening strategies: (I) postal invitation to colonoscopy and a re-invitation to colonoscopy for initial non-responders, (II) postal invitation for screening using fecal immunochemical test (FIT) for non-responders and subjects refusing a colonoscopy, or (III) postal invitation offering a choice between FIT and colonoscopy. Colonoscopies will be performed in seven local centers participating in the study. FITs will be analyzed in the central laboratory. Subjects with positive FIT result will be recommended to undergo colonoscopy. The primary outcome is participation with CRC screening within 18 weeks after enrollment, defined as completion of colonoscopy, or completion of FIT along with colonoscopy for positive FIT result. Secondary outcome will be diagnostic yield for advanced neoplasia (CRC or advanced adenoma). The study has been approved by a local bioethics committee.

NCT ID: NCT03789162 Recruiting - Colorectal Cancer Clinical Trials

Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion

Start date: December 20, 2018
Study type: Observational

The primary objective of this study is to collect de-identified, clinically-characterized stool and whole blood specimens for use in developing and evaluating the performance of new biomarker assays for the detection of colorectal cancer (CRC).

NCT ID: NCT03787537 Recruiting - Colorectal Cancer Clinical Trials

Nutritional Status and Nutrient Supply in Hospitalised Surgical Patients

Start date: August 1, 2017
Study type: Observational

Prospective single arm, single center observational study to assess the nutritional status and the nutrient supply during hospitalization for elective gastrointestinal surgery.

NCT ID: NCT03787056 Recruiting - Breast Cancer Clinical Trials

Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients

Start date: December 4, 2018
Phase: N/A
Study type: Interventional

Progastrin is a pro-hormone that, in physiological conditions, is maturated in gastrin in G cells of the stomach. The role of the gastrin is to stimulate the secretion of gastric acids during digestion. It is also important for the regulation of cell growth of the gastric mucosal. In a healthy person, progastrin is not detectable in the peripheral blood. However, progastrin is abnormally released in the blood of patients with different cancers (colorectal, gastric, ovarian, breast, cervix uterus, melanoma‚Ķ) The gene GAST coding for progastrin is a direct target gene of the WNT/ß-catenin oncogenic pathway. The activation of this oncogenic pathway is an early event in cancer development. Chronic activation of the WNT/ß-catenin oncogenic pathway occurs in almost all human solid tumors and is a central mechanism in cancer biology that induces cellular proliferation, blocking of differentiation leading to primary tumor growth and metastasis formation. Progastrin measured in the peripheral blood of patients on treatments, could be a new powerful marker for diagnosis and prognosis at different stages.

NCT ID: NCT03782428 Completed - Colorectal Cancer Clinical Trials

An Evaluation of Probiotic in the Clinical Course of Patients With Colorectal Cancer

Start date: August 26, 2016
Phase: N/A
Study type: Interventional

Colorectal cancer (CRC) is the most common cancer for men and the second most common for women. Several studies have shown that gut microbiome may play a role in triggering intestinal inflammation that leads to the development of CRC. Gut microbiome is the collection of microorganisms that inhabit the gut. Therefore, manipulation of the gut microbiome via administration of probiotics may potentially improve the health and nutritional status in patients with CRC. The aims of this study are to investigate the role of probiotic functional foods in reducing CRC-related inflammatory markers and symptom alleviation.Participants will be needed to complete an information details form which includes information on age, medical history, background details and diet. Participants are required to consume the investigational product twice daily for six months. Blood samples will be collected prior to surgery and at 6th months post product consumption. These blood samples will be processed and analysed.

NCT ID: NCT03781193 Recruiting - Colorectal Cancer Clinical Trials

Psychological Predictors in Colorectal Cancer Surgery Recovery

Start date: March 6, 2018
Study type: Observational

This is an observation pilot trial aimed to study to the association between mindfulness and other psychological factors, including both protective and risk factors, with recovery of functional ability following colorectal cancer surgery.

NCT ID: NCT03781154 Not yet recruiting - Colorectal Cancer Clinical Trials

Predictors of Physical Activity Maintenance in Colorectal Cancer Survivors

Start date: January 2019
Phase: Phase 3
Study type: Interventional

This study is a two-arm, randomized controlled trial, comparing the effects of a 12-week group-based physical activity intervention to a 1:1 supervised physical activity (i.e. personal training) on long-term physical activity adherence.